Jubilant Therapeutics, Inc.
Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. It employs an advanced discovery engine that integrates structure-based design and computational algorithms to develop novel, precision therapeutics targeting both first-in-class and validated but intractable targets in genetically-defined patient populations. The company leverages the proven and synergistic capabilities of Jubilant Pharmova's value chain and shared services, guided by renowned scientific advisory board members, and is headquartered in the U.S.
Industries
Nr. of Employees
small (1-50)
Jubilant Therapeutics, Inc.
790 Township Line Road, Suite 325, Yardley, PA 19067, USA
Patents
Substituted pyrimidine compounds, compositions and medicinal applications thereof
US-10273224-B2
View Details
Substituted pyrimidine compounds, compositions and medicinal applications thereof
US-10273224-B2
View DetailsProducts
Dual LSD1/HDAC6 small-molecule inhibitor (preclinical/IND-enabling)
A dual small-molecule inhibitor targeting lysine demethylase (LSD1) and HDAC6 that has demonstrated superior anti-proliferative activity and biomarker modulation in preclinical models and is undergoing IND-enabling studies.
PAD4 small-molecule inhibitors (preclinical)
Small-molecule inhibitors of peptidyl arginine deiminase 4 (PAD4) under preclinical evaluation to block NET formation and modulate inflammation-driven pathology.
PRMT5 small-molecule inhibitors (discovery/preclinical)
Discovery-stage small-molecule inhibitors of PRMT5 aimed at oncology indications, developed through structure-based approaches and preclinical evaluation.
Small-molecule PD-L1 modulators (discovery/preclinical)
Small-molecule approaches to modulate PD-L1 biology for oncology applications under discovery and preclinical advancement.
Dual LSD1/HDAC6 small-molecule inhibitor (preclinical/IND-enabling)
A dual small-molecule inhibitor targeting lysine demethylase (LSD1) and HDAC6 that has demonstrated superior anti-proliferative activity and biomarker modulation in preclinical models and is undergoing IND-enabling studies.
PAD4 small-molecule inhibitors (preclinical)
Small-molecule inhibitors of peptidyl arginine deiminase 4 (PAD4) under preclinical evaluation to block NET formation and modulate inflammation-driven pathology.
PRMT5 small-molecule inhibitors (discovery/preclinical)
Discovery-stage small-molecule inhibitors of PRMT5 aimed at oncology indications, developed through structure-based approaches and preclinical evaluation.
Small-molecule PD-L1 modulators (discovery/preclinical)
Small-molecule approaches to modulate PD-L1 biology for oncology applications under discovery and preclinical advancement.
Services
Collaborative discovery and development partnerships with biotech, pharma, academia and research institutes including in-licensing, combination studies and co-development.
Integration with biology-driven AI platforms and experimental workflows to identify biomarkers and select indications for targeted therapies.
Conduct of preclinical pharmacology, efficacy and IND-enabling studies to progress small-molecule candidates toward first-in-human trials.
Collaborative discovery and development partnerships with biotech, pharma, academia and research institutes including in-licensing, combination studies and co-development.
Integration with biology-driven AI platforms and experimental workflows to identify biomarkers and select indications for targeted therapies.
Conduct of preclinical pharmacology, efficacy and IND-enabling studies to progress small-molecule candidates toward first-in-human trials.
Expertise Areas
- Precision small-molecule discovery
- Preclinical pharmacology and translational research
- Biomarker discovery and patient stratification
- Epigenetic target drug discovery
Key Technologies
- Structure-based drug design
- Computational drug discovery algorithms
- Biology-driven artificial intelligence (AI)
- Small-molecule epigenetic modulators
News & Updates
Jubilant Therapeutics will participate in the Global Bio-India 2024 event in New Delhi from September 12-14, 2024.
The company announced that an abstract related to its dual LSD1 and HDAC6 inhibitor, JBI-802, was accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.
Jubilant Therapeutics announced a collaboration with The Wistar Institute to evaluate PAD4 inhibitors for blocking neutrophil extracellular trap formation in COVID-19 related cytokine storms.
The company announced the addition of Dr. Robert Glassman to its Board of Directors, bringing expertise in oncology, investment banking, and healthcare.
Jubilant Therapeutics will participate in the Global Bio-India 2024 event in New Delhi from September 12-14, 2024.
The company announced that an abstract related to its dual LSD1 and HDAC6 inhibitor, JBI-802, was accepted for presentation at the 62nd American Society of Hematology (ASH) Virtual Annual Meeting.
Jubilant Therapeutics announced a collaboration with The Wistar Institute to evaluate PAD4 inhibitors for blocking neutrophil extracellular trap formation in COVID-19 related cytokine storms.
The company announced the addition of Dr. Robert Glassman to its Board of Directors, bringing expertise in oncology, investment banking, and healthcare.